TG Therapeutics, Inc.
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), anā¦ read more
Healthcare
Biotechnology
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$27.73
Price-1.25%
-$0.35
1Y
Price
Market Cap
$4.400b
Mid
Price/Earnings 3y Avg5y Avg
73x
Premium
Premium
Financials Overview
Key metrics over the past few years-14.5%
EBITDA Margin-16.9%
Net Profit Margin-12.9%
Free Cash Flow MarginRevenue
$454.068m
+23.8%
1y CAGR+2751.8%
3y CAGR+3139.0%
5y CAGREarnings
$60.458m
+225.1%
1y CAGR+124.7%
3y CAGR+87.4%
5y CAGREPS
$0.37
+144.4%
1y CAGR+98.1%
3y CAGR+71.5%
5y CAGRBook Value
$237.289m
$656.689m
Assets$419.400m
Liabilities$254.583m
DebtDebt to Assets
38.8%
2.3x
Debt to EBITDAFree Cash Flow
-$61.095m
+164.6%
1y CAGR+95.7%
3y CAGR+62.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company